Nanotechnology-Employed Bacteria-Based Delivery Strategy for Enhanced Anticancer Therapy

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2021 Dec 22

PMID 34934313

Citations 12

Authors

Zixuan Ye

Lizhen Liang

Huazhen Lu

Yan Shen

Wenwu Zhou

Yanan Li

Affiliations

Soon will be listed here.

Abstract

Bacteria and their derivatives (membrane vesicles, MVs) exhibit great advantages for targeting hypoxic tumor cores, strong penetration ability and activating immune responses, holding great potential as auspicious candidates for therapeutic and drug-delivery applications. However, the safety issues and low therapeutic efficiency by single administration still need to be solved. To further optimize their performance and to utilize their natural abilities, scientists have strived to modify bacteria with new moieties on their surface while preserving their advantages. The aim of this review is to give a comprehensive overview of a non-genetic engineering modification strategy that can be used to optimize the bacteria with nanomaterials and the design strategy that can be used to optimize MVs for better targeted therapy. Here, the advantages and disadvantages of these processes and their applicability for the development of bacteria-related delivery system as antitumor therapeutic agents are discussed. The prospect and the challenges of the above targeted delivery system are also proposed.

Citing Articles

Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy.

Wang Y, Liu C, Fang C, Peng Q, Qin W, Yan X Nanomicro Lett. 2024; 17(1):30.

PMID: 39347944 PMC: 11442722. DOI: 10.1007/s40820-024-01533-y.

Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy.

Gholami A, Mohkam M, Soleimanian S, Sadraeian M, Lauto A Microsyst Nanoeng. 2024; 10:113.

PMID: 39166136 PMC: 11333603. DOI: 10.1038/s41378-024-00743-z.

Bacterial therapies at the interface of synthetic biology and nanomedicine.

Hahn J, Ding S, Im J, Harimoto T, Leong K, Danino T Nat Rev Bioeng. 2024; 2(2):120-135.

PMID: 38962719 PMC: 11218715. DOI: 10.1038/s44222-023-00119-4.

Adjusting laser power to control the heat generated by nanoparticles at the site of a patient's cells.

Razavi S, Khodadadi H, Goharimanesh M IET Syst Biol. 2024; 18(4):119-128.

PMID: 38789402 PMC: 11336058. DOI: 10.1049/syb2.12093.

Nanomaterials modulate tumor-associated macrophages for the treatment of digestive system tumors.

Li H, Wang S, Yang Z, Meng X, Niu M Bioact Mater. 2024; 36:376-412.

PMID: 38544737 PMC: 10965438. DOI: 10.1016/j.bioactmat.2024.03.003.

References

Wang X, Niu M, Fan J, Chen Q, Zhang X . Photoelectric Bacteria Enhance the Production of Tetrodotoxin for Antitumor Therapy. Nano Lett. 2021; 21(10):4270-4279. DOI: 10.1021/acs.nanolett.1c00408. View

Chen Q, Bai H, Wu W, Huang G, Li Y, Wu M . Bioengineering Bacterial Vesicle-Coated Polymeric Nanomedicine for Enhanced Cancer Immunotherapy and Metastasis Prevention. Nano Lett. 2019; 20(1):11-21. DOI: 10.1021/acs.nanolett.9b02182. View

Gao J, Wang S, Dong X, Wang Z . RGD-expressed bacterial membrane-derived nanovesicles enhance cancer therapy multiple tumorous targeting. Theranostics. 2021; 11(7):3301-3316. PMC: 7847689. DOI: 10.7150/thno.51988. View

Orench-Rivera N, Kuehn M . Environmentally controlled bacterial vesicle-mediated export. Cell Microbiol. 2016; 18(11):1525-1536. PMC: 5308445. DOI: 10.1111/cmi.12676. View

Singh A, Sitti M . Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design. Curr Pharm Des. 2015; 22(11):1418-28. DOI: 10.2174/1381612822666151210124326. View

Flickinger Jr J, Rodeck U, Snook A . as a Vector for Cancer Immunotherapy: Current Understanding and Progress. Vaccines (Basel). 2018; 6(3). PMC: 6160973. DOI: 10.3390/vaccines6030048. View

Kim J, Doody A, Chen D, Cremona G, Shuler M, Putnam D . Engineered bacterial outer membrane vesicles with enhanced functionality. J Mol Biol. 2008; 380(1):51-66. PMC: 4617544. DOI: 10.1016/j.jmb.2008.03.076. View

Russo A, Behl B, Banerjee I, Rathinam V . Emerging Insights into Noncanonical Inflammasome Recognition of Microbes. J Mol Biol. 2017; 430(2):207-216. PMC: 5790197. DOI: 10.1016/j.jmb.2017.10.003. View

Wang X, Cao Z, Zhang M, Meng L, Ming Z, Liu J . Bioinspired oral delivery of gut microbiota by self-coating with biofilms. Sci Adv. 2020; 6(26):eabb1952. PMC: 7314526. DOI: 10.1126/sciadv.abb1952. View

10.

Imberti C, Zhang P, Huang H, Sadler P . New Designs for Phototherapeutic Transition Metal Complexes. Angew Chem Int Ed Engl. 2019; 59(1):61-73. PMC: 6973108. DOI: 10.1002/anie.201905171. View

11.

Basle A, Rummel G, Storici P, Rosenbusch J, Schirmer T . Crystal structure of osmoporin OmpC from E. coli at 2.0 A. J Mol Biol. 2006; 362(5):933-42. DOI: 10.1016/j.jmb.2006.08.002. View

12.

Pautsch A, Schulz G . Structure of the outer membrane protein A transmembrane domain. Nat Struct Biol. 1998; 5(11):1013-7. DOI: 10.1038/2983. View

13.

Garcia-Diaz A, Shin D, Moreno B, Saco J, Escuin-Ordinas H, Rodriguez G . Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2019; 29(11):3766. DOI: 10.1016/j.celrep.2019.11.113. View

14.

M Pawelek J, Low K, Bermudes D . Bacteria as tumour-targeting vectors. Lancet Oncol. 2003; 4(9):548-56. DOI: 10.1016/s1470-2045(03)01194-x. View

15.

Morales A, Eidinger D, Bruce A . Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol. 2002; 167(2 Pt 2):891-3; discussion 893-5. DOI: 10.1016/s0022-5347(02)80294-4. View

16.

Li Y, Zhao R, Cheng K, Zhang K, Wang Y, Zhang Y . Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy Immune Activation and Checkpoint Inhibition. ACS Nano. 2020; 14(12):16698-16711. DOI: 10.1021/acsnano.0c03776. View

17.

Couvreur P . Nanoparticles in drug delivery: past, present and future. Adv Drug Deliv Rev. 2012; 65(1):21-3. DOI: 10.1016/j.addr.2012.04.010. View

18.

Wang S, Huang W, Li K, Yao Y, Yang X, Bai H . Engineered outer membrane vesicle is potent to elicit HPV16E7-specific cellular immunity in a mouse model of TC-1 graft tumor. Int J Nanomedicine. 2017; 12:6813-6825. PMC: 5602458. DOI: 10.2147/IJN.S143264. View

19.

Whittle J, Lickliter J, Gan H, Scott A, Simes J, Solomon B . First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma. J Clin Neurosci. 2015; 22(12):1889-94. DOI: 10.1016/j.jocn.2015.06.005. View

20.

Yu B, Tai H, Xue W, Lee L, Lee R . Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010; 27(7):286-98. PMC: 3789246. DOI: 10.3109/09687688.2010.521200. View